MedTrace Logo

Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)

NCT04946500 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-07-01

No results posted yet for this study

Summary

The alternatives to the combination of Fluoroquinolone and Rifampicin in prosthetic joint infections (PJI) caused by staphylococcus are currently unclear. Clindamycin is prescribed as dual therapy in this indication, and provides many advantages. We conducted a multicenter retrospective observational study evaluating the efficacy and safety of Clindamycin in prosthetic joint infections due to staphylococcus between January 2013 and December 2019.

Conditions

  • Prosthetic Joint Infection
  • Staphylococcus

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2021-07-15
Completion
2021-10-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04946500 on ClinicalTrials.gov